McDermott Advises Inventiva on its Research Project with Boehringer Ingelheim
PARIS (June 13, 2016) – International law firm McDermott Will & Emery advised Inventiva, a French biopharmaceutical company specializing in the development of innovative therapies for fibrosis, oncology and orphan diseases, on its cooperation and licensing agreement with Boehringer Ingelheim.
Under the terms of the agreement, which closed on 1 June 2016, Inventiva and Boehringer Ingelheim’s research teams will jointly validate a new therapeutic concept with the aim of discovering new medicines for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases. The partnership will combine Inventiva’s knowhow and proprietary technologies in the field of transcriptional regulation and fibrosis with Boehringer Ingelheim’s capabilities in drug discovery and clinical development of new therapeutic agents.
Inventiva will receive an upfront payment and will also be eligible to receive research funding of up to €170 million, as well as tiered royalties on net sales of the products resulting from the partnership.
The McDermott team included partners Emmanuelle Trombe and Anthony Paronneau and associate Raphaëlle Monjou.
McDermott’s Life Sciences Group works with clients to structure collaborative arrangements among emerging life sciences companies, established pharmaceutical and biotech companies and researchers and research institutions. These arrangements range from licensing technology to and from academic medical centres, universities and other research institutions, to complex strategic alliances among life sciences companies to achieve varied financial, research and development, manufacturing and distribution objectives. The Firm’s long-term experience in advising pharmaceuticals and agrochemical companies on taxation issues allows us to devise structures and tax plans for life sciences companies who wish to be attractive partners or acquisition candidates for the pharmaceutical industry.
McDermott Will & Emery is a premier international law firm with a diversified business practice. Numbering more than 1,000 lawyers, we have offices in Boston, Brussels, Chicago, Dallas, Düsseldorf, Frankfurt, Houston, London, Los Angeles, Miami, Milan, Munich, New York, Orange County, Paris, Rome, Seoul, Silicon Valley and Washington, D.C. Further extending our reach into Asia, we have a strategic alliance with MWE China Law Offices in Shanghai.